default author photo

Astrid Lievre

Université de Rennes 1 - CHU de Rennes

SCHOLARLY PAPERS

2

DOWNLOADS

195

TOTAL CITATIONS

0

Scholarly Papers (2)

1.

Pembrolizumab in Combination with CAPOX and Bevacizumab in Patients with Microsatellite Stable Metastatic Colorectal Cancer and a High Immune Infiltrate: Preliminary Results of the Single-Arm, Phase II, Open-Label FFCD 1703-POCHI Trial

Number of pages: 23 Posted: 09 Dec 2024
Université de Poitiers - Gastroenterology Department, Assistance Publique-Hôpitaux de Paris - Department of Pathology, Ambroise Paré, Saint-Malo Hospital Centre, University of Franche-Comté, Hôpital Saint Joseph, Centre François Baclesse, University of Limoges, Centre Hospitalier Général de Quimper, Hôpital Franco-Britannique, Perpignan Hospital Center, Infirmerie Protestante, Caluire et Cuire, Roche-Sur-Yon Hospital, Université de Rennes 1 - CHU de Rennes, Sainte Catherine Institute, Hôpital Franco-Britannique, University of Lorraine - Department of Hepatogastroenterology, University of Franche-Comté, Universite Paris Descartes, Université Paris VI Pierre et Marie Curie - Immunity & Cancer, Assistance Publique-Hopitaux de Paris (AP-HP) - Hôpital Européen Georges Pompidou, Université Paris Cité, Université Paris Cité, Clinique Saint Anne, Université Paris Cité and Independent
Downloads 139 (530,816)

Abstract:

Loading...

colorectal cancer, immune score, adenocarcinoma, chemotherapy, immune checkpoint inhibitor

2.

Pemigatinib-associated toxicity and its management: implications on prognosis in patients with cholangiocarcinoma treated within real-world Italian PEMIREAL and French PEMIBIL cohorts

Number of pages: 20 Posted: 17 Dec 2025
affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Centre Hospitalier Universitaire de Toulouse, affiliation not provided to SSRN, Gustave Roussy - Drug Development Department (DITEP), University of Bordeaux - Hôpital Haut-Lévêque, affiliation not provided to SSRN, University of Montpellier - Institut régional du Cancer de Montpellier, Centre Paul Strauss, University of Claude Bernard Lyon 1 - Centre Léon Bérard, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Pisa, University of Perugia, affiliation not provided to SSRN, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Academic Hospital of Udine ASUFC - Department of Oncology, Université de Poitiers - Gastroenterology Department, affiliation not provided to SSRN, affiliation not provided to SSRN, Università Vita-Salute San Raffaele - IRCCS San Raffaele Scientific Institute, Università Vita-Salute San Raffaele - IRCCS Ospedale San Raffaele, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Milano-Bicocca - Fondazione IRCCS San Gerardo dei Tintori, affiliation not provided to SSRN, affiliation not provided to SSRN, Centre Antoine Lacassagne, affiliation not provided to SSRN, University of Lille - CHU Lille, Institut de Cancérologie de l'Ouest - Department of Medical Oncology, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Institut Mutualiste Montsouris, École Normale Supérieure - PSL Research University - Institut Curie, Centre Eugène Marquis - Medical Oncology, Université de Rennes 1 - CHU de Rennes, University of Toulouse - Hospital Rangueil, IRCCS Humanitas Research Hospital, affiliation not provided to SSRN, Centre Hospitalier Universitaire de Toulouse and affiliation not provided to SSRN
Downloads 56 (1,041,696)

Abstract:

Loading...

Drug toxicity, adverse events, Cholangiocarcinoma, biliary tract cancer, FGFR2 fusions/rearrangements, Real-world Evidence, Systemic treatment, targeted therapy